BR112022020058A2 - N-cianopirrolidinas com atividade como inibidores de usp30 - Google Patents
N-cianopirrolidinas com atividade como inibidores de usp30Info
- Publication number
- BR112022020058A2 BR112022020058A2 BR112022020058A BR112022020058A BR112022020058A2 BR 112022020058 A2 BR112022020058 A2 BR 112022020058A2 BR 112022020058 A BR112022020058 A BR 112022020058A BR 112022020058 A BR112022020058 A BR 112022020058A BR 112022020058 A2 BR112022020058 A2 BR 112022020058A2
- Authority
- BR
- Brazil
- Prior art keywords
- cyanopyrrolidines
- activity
- inhibitors
- usp30
- usp30 inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005250.2A GB202005250D0 (en) | 2020-04-08 | 2020-04-08 | Novel compounds |
| GBGB2016607.0A GB202016607D0 (en) | 2020-10-20 | 2020-10-20 | Novel Compounds |
| PCT/EP2021/059032 WO2021204856A1 (en) | 2020-04-08 | 2021-04-07 | N-cyanopyrrolidines with activity as usp30 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020058A2 true BR112022020058A2 (pt) | 2022-11-22 |
Family
ID=75441909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020058A BR112022020058A2 (pt) | 2020-04-08 | 2021-04-07 | N-cianopirrolidinas com atividade como inibidores de usp30 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230119013A1 (enExample) |
| EP (1) | EP4132925A1 (enExample) |
| JP (1) | JP2023520727A (enExample) |
| KR (1) | KR20230006487A (enExample) |
| CN (1) | CN115461340A (enExample) |
| AU (1) | AU2021253617A1 (enExample) |
| BR (1) | BR112022020058A2 (enExample) |
| CA (1) | CA3171349A1 (enExample) |
| CO (1) | CO2022014134A2 (enExample) |
| IL (1) | IL296998A (enExample) |
| MX (1) | MX2022012578A (enExample) |
| WO (1) | WO2021204856A1 (enExample) |
| ZA (1) | ZA202212137B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021245186A1 (en) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| RS67140B1 (sr) | 2020-06-08 | 2025-09-30 | Mission Therapeutics Ltd | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| CN117887844B (zh) * | 2023-12-28 | 2024-08-23 | 中山大学附属第一医院 | Usp20在肝癌放疗增敏中的应用 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
| GB202500610D0 (en) | 2025-01-16 | 2025-03-05 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| JP2003530384A (ja) | 2000-04-06 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | カテプシンシステインプロテアーゼ阻害薬 |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2007119214A2 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| US20090264431A1 (en) | 2007-08-20 | 2009-10-22 | Palovich Michael R | Novel cathepsin c inhibitors and their use |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| UY31770A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
| UY31771A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| JP6612751B2 (ja) | 2013-07-31 | 2019-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| US20170095457A1 (en) | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| LT3277677T (lt) * | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| MA43753A (fr) * | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) * | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| AU2018346597B2 (en) * | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP3837262B1 (en) * | 2018-08-14 | 2026-06-17 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| EP4218934B1 (en) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
-
2021
- 2021-04-07 MX MX2022012578A patent/MX2022012578A/es unknown
- 2021-04-07 KR KR1020227038744A patent/KR20230006487A/ko not_active Withdrawn
- 2021-04-07 WO PCT/EP2021/059032 patent/WO2021204856A1/en not_active Ceased
- 2021-04-07 US US17/914,414 patent/US20230119013A1/en not_active Abandoned
- 2021-04-07 CA CA3171349A patent/CA3171349A1/en active Pending
- 2021-04-07 JP JP2022561565A patent/JP2023520727A/ja active Pending
- 2021-04-07 EP EP21717825.0A patent/EP4132925A1/en not_active Withdrawn
- 2021-04-07 CN CN202180023434.1A patent/CN115461340A/zh active Pending
- 2021-04-07 BR BR112022020058A patent/BR112022020058A2/pt not_active IP Right Cessation
- 2021-04-07 IL IL296998A patent/IL296998A/en unknown
- 2021-04-07 AU AU2021253617A patent/AU2021253617A1/en not_active Abandoned
-
2022
- 2022-09-30 CO CONC2022/0014134A patent/CO2022014134A2/es unknown
- 2022-11-07 ZA ZA2022/12137A patent/ZA202212137B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3171349A1 (en) | 2021-10-14 |
| CO2022014134A2 (es) | 2022-10-31 |
| EP4132925A1 (en) | 2023-02-15 |
| CN115461340A (zh) | 2022-12-09 |
| WO2021204856A1 (en) | 2021-10-14 |
| IL296998A (en) | 2022-12-01 |
| KR20230006487A (ko) | 2023-01-10 |
| AU2021253617A1 (en) | 2022-12-01 |
| MX2022012578A (es) | 2022-11-07 |
| JP2023520727A (ja) | 2023-05-18 |
| US20230119013A1 (en) | 2023-04-20 |
| ZA202212137B (en) | 2024-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022003527A2 (pt) | Cianopirrolidinas substituídas com atividade como inibidores de usp30 | |
| BR112022019722A2 (pt) | N-cianopirrolidinas com atividade como inibidores de usp30 | |
| BR112022024794A2 (pt) | Hexahidropirrolo[3,4-b]pirrolo-5(1h)-carbonitrilas com atividade como inibidores de usp30 para uso no tratamento de disfunção mitocondrial, câncer e fibrose | |
| CO2022014134A2 (es) | N-cianopirrolidinas con actividad como inhibidores de usp30 | |
| CO2019014682A2 (es) | Composiciones y métodos para enzimas de internalización | |
| MX2022009056A (es) | Inhibidores de integrina ?v?6. | |
| CO2017007863A2 (es) | Ácidos 3-alquil-4-amido-bicíclico [4,5,0] hidroxámico como inhibidores de hdac | |
| EA201101053A1 (ru) | Ингибиторы фосфоиноз итид-3-киназ с цинксвязывающей группой | |
| CR20170014A (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| MX2018005925A (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| BR112022020644A2 (pt) | Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial | |
| BR112018000254A2 (pt) | inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas | |
| BR112015029240A2 (pt) | composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo | |
| EA202091205A1 (ru) | Композиции для терапии гипергликемии и сопутствующих состояний | |
| BR112022014962A2 (pt) | Terapia de combinação para tratamento de câncer e metástase de câncer | |
| BR112016000658A2 (pt) | pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática | |
| MX2023012851A (es) | Métodos de tratamiento y seguimiento de la enfermedad de parkinson. | |
| BR112022008938A2 (pt) | Derivados de 1-aminossulfonil-2-carboxipirrol como inibidores de metalo-beta-lactamase | |
| MX384262B (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| AR118696A1 (es) | Administración mejorada de vectores de tratamiento génico a células retinianas mediante el uso de una enzima glicósido hidrolasa | |
| UY35695A (es) | Composicion para el tratamiento contra el envejecimiento de la piel | |
| MX2021002814A (es) | Microorganismo para la produccion de l-aminoacido con actividad mejorada de a-glucosidasa y procedimiento para la produccion de l-aminoacido usando el mismo. | |
| BR112015011693A2 (pt) | composições fibrinolíticas compreendendo bromelina e nattokinase para a prevenção e tratamento de estados flebotrombóticos | |
| MX2021014015A (es) | Metodos basados en el genoma para reducir el riesgo cardiovascular. | |
| BR112022006125A2 (pt) | Composições compreendendo hialuronidase e/ou colagenase e/ou 4-metilumbeliferona (4-mu) e métodos de tratamento usando as mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2874 DE 03/02/2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 17, DA PORTARIA 52/2023. |